CSL Awarded US Government Contract
News Sep 12, 2012
CSL Biotherapies has been awarded a contract by the U.S. Department of Health and Human Services to supply pre-pandemic and pandemic vaccine antigens and related services to the U.S. national stockpile.
Under the terms of the contract, the U.S. Government may request CSL Biotherapies to manufacture and store bulk antigen that can be used against influenza strains with pandemic potential. The Company may also be called upon to develop working virus 'seeds' for other manufacturers and to formulate, fill and finish bulk stored antigen.
"We are very pleased to again be working with the U.S. Government on its pandemic preparedness efforts," said Dr. John Anderson, Senior Vice President of CSL Biotherapies. "CSL Biotherapies is committed to helping to protect the American public against the potential impact of an influenza pandemic. We are proud to contribute our 45 years of successful influenza vaccine manufacturing experience to the U.S. National Strategy for Pandemic Influenza."
Funding for the CSL Biotherapies contract is provided solely by the U.S. Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority, under contract No HHSO100201200011I. The contract has a maximum potential value of $1,511,407,737.78 if all optional activities are exercised over the duration of the contract.
With their ability to treat a wide a variety of diseases, spherical nucleic acids are poised to revolutionize medicine. But before these digitally designed nanostructures can reach their full potential, researchers need to optimize their various components. A team has developed a direct route to optimize these particles, bringing them one step closer to becoming a viable treatment option for numerous diseases, including cancer.READ MORE
15th International Conference on Surgical Pathology and Cancer Diagnosis
Apr 15 - Apr 16, 2019